EYESERV GMBH has a total of 18 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2016. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and biotechnology are LEIDS UNI MEDISCH CT, GLEAVE MARTIN and INTROGEN THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Australia | 2 | |
#4 | Brazil | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | Israel | 2 | |
#8 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Biel Martin | 14 |
#2 | Seeliger Mathias | 14 |
#3 | Michalakis Stylianos | 14 |
#4 | Schoen Christian | 6 |
#5 | Martin Biel | 4 |
#6 | Stylianos Michalakis | 4 |
#7 | Mathias Seeliger | 4 |
#8 | Christian Schoen | 2 |
#9 | Schön Christian | 1 |
Publication | Filing date | Title |
---|---|---|
EP3210632A1 | Gene therapy for the treatment of a retinal degeneration disease | |
WO2017144080A1 | Gene therapy for the treatment of a disease of retinal cone cells |